Acurx Pharmaceuticals (ACXP) Change in Accured Expenses (2020 - 2026)
Acurx Pharmaceuticals' (ACXP) quarterly Change in Accured Expenses came in at $105866.0 in Q1 2026, up 131.54% YoY from $45722.6 in Q1 2025, and up 324.14% on a QoQ basis from -$47232.0 in Q4 2025.
Acurx Pharmaceuticals (ACXP) Change in Accured Expenses (2020 - 2026) Analysis & Trends
Acurx Pharmaceuticals (ACXP) has 7 years of Change in Accured Expenses data on file, last reported at $105866.0 in Q1 2026.
- Quarterly Change in Accured Expenses rose 131.54% year-over-year to $105866.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32747.0 (up 116.13% YoY) and the FY2025 annual result came in at -$408779.0, down 303.98% from the prior year.
- Change in Accured Expenses rose to $105866.0 in Q1 2026, from -$47232.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $945426.0 in Q2 2023 to a low of -$335660.0 in Q1 2025.
- A 5-year average of $123295.3 and a median of $42675.0 in 2024 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses slumped 1694.12% — and 2023, when it surged 694.05%.
- Tracing ACXP's Change in Accured Expenses over 5 years: stood at $879605.0 in 2022, then plunged by 120.57% to -$180940.0 in 2023, then jumped by 58.04% to -$75923.0 in 2024, then jumped by 37.79% to -$47232.0 in 2025, then surged by 324.14% to $105866.0 in 2026.
- The last three Change in Accured Expenses figures came in at $105866.0 (Q1 2026), -$47232.0 (Q4 2025), and -$123352.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Acurx Pharmaceuticals | 6.38 Mn | 6.38 Mn | - | 305,937.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 305,937.00 |
| Jun 30, 2026 | 305,937.00 |
| Mar 31, 2026 | 105,866.00 |
| Mar 31, 2026 | 105,866.00 |
| Dec 31, 2025 | -47,232.00 |
| Dec 31, 2025 | -47,232.00 |
| Sep 30, 2025 | -123,352.00 |
| Sep 30, 2025 | -123,352.00 |
| Jun 30, 2025 | 97,465.00 |
| Jun 30, 2025 | 97,465.00 |
| Mar 31, 2025 | -335,660.00 |
| Mar 31, 2025 | -335,660.00 |
| Dec 31, 2024 | -75,923.00 |
| Dec 31, 2024 | -75,923.00 |
| Sep 30, 2024 | 165,848.00 |
| Sep 30, 2024 | 165,848.00 |
| Jun 30, 2024 | 42,675.00 |
| Jun 30, 2024 | 42,675.00 |
| Mar 31, 2024 | 67,804.00 |
| Mar 31, 2024 | 67,804.00 |